CLVS - クロビス・オンコロジ― (Clovis Oncology Inc.) クロビス・オンコロジ―

 CLVSのチャート


 CLVSの企業情報

symbol CLVS
会社名 Clovis Oncology Inc (クロビス・オンコロジ―)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 クロービス・オンコロジー(Clovis Oncology Inc.)は米国、ヨーロッパ及び他の国際市場における抗癌剤の取得・開発・商品化に従事するバイオ医薬品会社である。同社の製品候補にはロシリチニブ、ルブラカ(ルカパリブ)及びルシチニブを含む。ルカパリブは損傷デオキシリボ核酸乳癌(DNA)の修復関連ヒト遺伝子の乳がん(BRCA)突然変異患者の治療向け単剤療法として承認されたPARP1、PARP2及びPARP3の経口小分子ポリアデノシン二リン酸(ADP)・リボースポリメラーゼ(PARP)阻害剤である。ルシチニブは、血管内皮増殖因子受容体(VEGFR)1-3、血小板由来増殖因子受容体(PDGFR)αとβ及び線維芽細胞増殖因子受容体(FGFR)1-3のチロシンキナーゼ活性の経口阻害剤である。ロシリチニブは表皮成長因子受容体(EGFR)の経口突然変異選択的阻害剤である。   クロビス・オンコロジ―は米国のバイオ医薬品会社。抗がん剤の買収、開発、商業化を手掛ける。非小細胞肺がん治療用に経口の選択的・非可逆的EGFR阻害剤CO-186を、また、卵巣がんおよびすい臓がん治療用にポリ(ADP-リボ―ス)ポリメラ―ゼ阻害剤ルカパリブの臨床開発を実施している。   
本社所在地 5500 Flatiron Parkway Suite 100 Boulder CO 80301 USA
代表者氏名 M. James E. Barrett M.ジェームスE.バレット
代表者役職名 Independent Chairman of the Board
電話番号 +1 303-625-5000
設立年月日 39904
市場名 NASDAQ National Market System
ipoyear 2011年
従業員数 360人
url www.clovisoncology.com
nasdaq_url https://www.nasdaq.com/symbol/clvs
adr_tso
EBITDA EBITDA(百万ドル) -268.68600
終値(lastsale) 30.34
時価総額(marketcap) 1597388590.94
時価総額 時価総額(百万ドル) 1531.05
売上高 売上高(百万ドル) 76.12600
企業価値(EV) 企業価値(EV)(百万ドル) 1423.143
当期純利益 当期純利益(百万ドル) -129.23100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Clovis Oncology Inc revenues increased 95% to $42.3M. Net loss decreased 24% to $178.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Legal settlement loss decrease of 93% to $8M (expense) Other income increase from $948K to $2.9M (income).

 CLVSのテクニカル分析


 CLVSのニュース

   Nasdaq delists securities of Tuscan Holdings, Clovis Oncology, Zyversa Therapeutics  2022/12/28 22:09:37 Seeking Alpha
The Nasdaq stock announced on Wednesday delisting of securities of Tuscan Holdings Corp
   Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket  2022/12/14 11:30:12 Benzinga
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON ) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio. Crown ElectroKinetics Corp. (NASDAQ: CRKN ) shares rose 71.2% to $0.2243 in pre-market trading after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. Versus Systems Inc. (NASDAQ: VS ) rose 28% to $1.00 in pre-market trading after gaining around 7% on Tuesday. Versus Systems recently announced pricing of a $2.1 million public offering. Senti Biosciences, Inc. (NASDAQ: SNTI ) rose 17.4% to $1.69 in pre-market trading after dipping more than 21% on Tuesday. Scopus BioPharma Inc. (NASDAQ: SCPS ) shares rose 15.8% to $0.2839 in pre-market trading. Clovis Oncology, Inc. (NASDAQ: CLVS ) rose 12.8% to $0.1503 in pre-market trading after dropping 34% on Tuesday. Clovis Oncology voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its assets through a court-supervised sales process.
   Wall Street’s Take On Clovis Oncology Inc. (NASDAQ: CLVS) Stock.  2022/12/13 13:00:00 Stocks Register
Clovis Oncology Inc. (NASDAQ:CLVS) traded at $0.20 at close of the session on Monday, 12/12/22, made an upward move of 0.65% on its previous day’s price. Looking at the stock we see that its previous close was $0.20 and the beta (5Y monthly) reads 0.47 with the day’s price range being $0.172 – $0.275. In … Wall Street’s Take On Clovis Oncology Inc. (NASDAQ: CLVS) Stock. Read More »
   Clovis Oncology files Chapter 11, agrees to sell a drug asset  2022/12/12 22:56:23 Daily Camera
Boulder-based Clovis Oncology Inc. (Nasdaq: CLVS) filed for Chapter 11 bankruptcy protection Sunday. Its filing claims liabilities far exceeding assets.
   Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis  2022/12/12 19:05:00 The Wall Street Journal
Clovis Oncology, maker of ovarian cancer drug Rubraca, has filed for chapter 11 and proposed selling a separate therapy to a Novartis affiliate.
   Nasdaq delists securities of Tuscan Holdings, Clovis Oncology, Zyversa Therapeutics  2022/12/28 22:09:37 Seeking Alpha
The Nasdaq stock announced on Wednesday delisting of securities of Tuscan Holdings Corp
   Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket  2022/12/14 11:30:12 Benzinga
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON ) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio. Crown ElectroKinetics Corp. (NASDAQ: CRKN ) shares rose 71.2% to $0.2243 in pre-market trading after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. Versus Systems Inc. (NASDAQ: VS ) rose 28% to $1.00 in pre-market trading after gaining around 7% on Tuesday. Versus Systems recently announced pricing of a $2.1 million public offering. Senti Biosciences, Inc. (NASDAQ: SNTI ) rose 17.4% to $1.69 in pre-market trading after dipping more than 21% on Tuesday. Scopus BioPharma Inc. (NASDAQ: SCPS ) shares rose 15.8% to $0.2839 in pre-market trading. Clovis Oncology, Inc. (NASDAQ: CLVS ) rose 12.8% to $0.1503 in pre-market trading after dropping 34% on Tuesday. Clovis Oncology voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its assets through a court-supervised sales process.
   Wall Street’s Take On Clovis Oncology Inc. (NASDAQ: CLVS) Stock.  2022/12/13 13:00:00 Stocks Register
Clovis Oncology Inc. (NASDAQ:CLVS) traded at $0.20 at close of the session on Monday, 12/12/22, made an upward move of 0.65% on its previous day’s price. Looking at the stock we see that its previous close was $0.20 and the beta (5Y monthly) reads 0.47 with the day’s price range being $0.172 – $0.275. In … Wall Street’s Take On Clovis Oncology Inc. (NASDAQ: CLVS) Stock. Read More »
   Clovis Oncology files Chapter 11, agrees to sell a drug asset  2022/12/12 22:56:23 Daily Camera
Boulder-based Clovis Oncology Inc. (Nasdaq: CLVS) filed for Chapter 11 bankruptcy protection Sunday. Its filing claims liabilities far exceeding assets.
   Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis  2022/12/12 19:05:00 The Wall Street Journal
Clovis Oncology, maker of ovarian cancer drug Rubraca, has filed for chapter 11 and proposed selling a separate therapy to a Novartis affiliate.
   Nasdaq delists securities of Tuscan Holdings, Clovis Oncology, Zyversa Therapeutics  2022/12/28 22:09:37 Seeking Alpha
The Nasdaq stock announced on Wednesday delisting of securities of Tuscan Holdings Corp
   Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket  2022/12/14 11:30:12 Benzinga
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON ) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio. Crown ElectroKinetics Corp. (NASDAQ: CRKN ) shares rose 71.2% to $0.2243 in pre-market trading after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. Versus Systems Inc. (NASDAQ: VS ) rose 28% to $1.00 in pre-market trading after gaining around 7% on Tuesday. Versus Systems recently announced pricing of a $2.1 million public offering. Senti Biosciences, Inc. (NASDAQ: SNTI ) rose 17.4% to $1.69 in pre-market trading after dipping more than 21% on Tuesday. Scopus BioPharma Inc. (NASDAQ: SCPS ) shares rose 15.8% to $0.2839 in pre-market trading. Clovis Oncology, Inc. (NASDAQ: CLVS ) rose 12.8% to $0.1503 in pre-market trading after dropping 34% on Tuesday. Clovis Oncology voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its assets through a court-supervised sales process.
   Wall Street’s Take On Clovis Oncology Inc. (NASDAQ: CLVS) Stock.  2022/12/13 13:00:00 Stocks Register
Clovis Oncology Inc. (NASDAQ:CLVS) traded at $0.20 at close of the session on Monday, 12/12/22, made an upward move of 0.65% on its previous day’s price. Looking at the stock we see that its previous close was $0.20 and the beta (5Y monthly) reads 0.47 with the day’s price range being $0.172 – $0.275. In … Wall Street’s Take On Clovis Oncology Inc. (NASDAQ: CLVS) Stock. Read More »
   Clovis Oncology files Chapter 11, agrees to sell a drug asset  2022/12/12 22:56:23 Daily Camera
Boulder-based Clovis Oncology Inc. (Nasdaq: CLVS) filed for Chapter 11 bankruptcy protection Sunday. Its filing claims liabilities far exceeding assets.
   Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis  2022/12/12 19:05:00 The Wall Street Journal
Clovis Oncology, maker of ovarian cancer drug Rubraca, has filed for chapter 11 and proposed selling a separate therapy to a Novartis affiliate.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 クロビス・オンコロジ― CLVS Clovis Oncology Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)